Opthea Developing Therapy for Eye Diseases

Opthea is developing novel therapies for the treatment of eye diseases.

Opthea's lead compound, OPT-302, blocks two members of the vascular endothelial growth factor family, namely VEGF-C and   VEGF-D, which cause blood vessels to grow and leak. Aberrant blood vessel growth and vascular leakage are hallmarks of several eye diseases including wet age-related macular degeneration (wet AMD).

Opthea is currently investigating OPT-302 in an ongoing Phase 1/2A clinical trial in wet AMD patients. 

Latest News

09 AUG 2016. “Opthea Presents at Ophthalmology Innovation Summit in US"

read more >>

26 JUL 2016. “Opthea Reports Positive Data from Wet AMD Clinical Trial"

read more >>

25 JUL 2016. “Opthea to Host Conference Call Update on Wet AMD Trial"

read more >>

21 APR 2016. “Opthea Phase 1 wet AMD Clinical Trial with OPT-302 Meets Primary Safety Objective"

read more >>
Share Price